CO2022001829A2 - Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso - Google Patents

Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso

Info

Publication number
CO2022001829A2
CO2022001829A2 CONC2022/0001829A CO2022001829A CO2022001829A2 CO 2022001829 A2 CO2022001829 A2 CO 2022001829A2 CO 2022001829 A CO2022001829 A CO 2022001829A CO 2022001829 A2 CO2022001829 A2 CO 2022001829A2
Authority
CO
Colombia
Prior art keywords
prolgolimab
antibody
pharmaceutical composition
aqueous pharmaceutical
pharmaceutical compositions
Prior art date
Application number
CONC2022/0001829A
Other languages
English (en)
Inventor
Dmitry Valentinovich Morozov
Ekaterina Aleksandrovna Lomkova
Viktoriia Olegovna Shitikova
Aleksandr Olegovich Iakovlev
Mariia Stanislavovna Shustova
Alina Aleksandrovna Tsukur
Olesya Nikolaevna Kozlova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2019126511A external-priority patent/RU2806320C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CO2022001829A2 publication Critical patent/CO2022001829A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las composiciones farmacéuticas acuosas para el anticuerpo anti-PD-1 prolgolimab y al uso de dichas composiciones farmacéuticas como agente medicinal para el tratamiento de enfermedades mediadas por PD-1.
CONC2022/0001829A 2019-08-22 2022-02-21 Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso CO2022001829A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019126511A RU2806320C2 (ru) 2019-08-22 Водная фармацевтическая композиция антитела к pd-1 пролголимаба и ее применение
PCT/RU2020/050197 WO2021034228A1 (ru) 2019-08-22 2020-08-21 Водная фармацевтическая композиция антитела к pd-1 пролголимаба и ее применение

Publications (1)

Publication Number Publication Date
CO2022001829A2 true CO2022001829A2 (es) 2022-03-29

Family

ID=71558267

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001829A CO2022001829A2 (es) 2019-08-22 2022-02-21 Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso

Country Status (18)

Country Link
EP (1) EP4019047A4 (es)
JP (1) JP2022544850A (es)
KR (1) KR20220147061A (es)
CN (1) CN111420049A (es)
AR (1) AR119805A1 (es)
AU (1) AU2020333023A1 (es)
BR (1) BR112022003378A2 (es)
CA (1) CA3148978A1 (es)
CO (1) CO2022001829A2 (es)
EC (1) ECSP22021881A (es)
JO (1) JOP20220045A1 (es)
MA (2) MA61742A1 (es)
MX (1) MX2022002185A (es)
PE (1) PE20220932A1 (es)
TW (1) TWI844666B (es)
UY (1) UY38851A (es)
WO (1) WO2021034228A1 (es)
ZA (1) ZA202202243B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111965372B (zh) * 2020-09-03 2024-05-31 北京安图生物工程有限公司 免疫球蛋白e检测试剂盒及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61029B1 (sr) * 2015-12-07 2020-12-31 Merck Patent Gmbh Vodena formulacija koja sadrži avelumab antitelo na pd-1
EP3848393A1 (en) * 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
WO2019122941A1 (en) * 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule

Also Published As

Publication number Publication date
MA61742A1 (fr) 2023-11-30
RU2019126511A3 (es) 2021-04-30
MX2022002185A (es) 2022-04-20
JOP20220045A1 (ar) 2023-01-30
RU2019126511A (ru) 2021-02-24
AR119805A1 (es) 2022-01-12
WO2021034228A1 (ru) 2021-02-25
BR112022003378A2 (pt) 2022-05-17
TWI844666B (zh) 2024-06-11
AU2020333023A1 (en) 2022-11-03
JP2022544850A (ja) 2022-10-21
TW202114637A (zh) 2021-04-16
EP4019047A1 (en) 2022-06-29
ZA202202243B (en) 2024-09-25
KR20220147061A (ko) 2022-11-02
PE20220932A1 (es) 2022-05-31
MA56263A1 (fr) 2022-11-30
CN111420049A (zh) 2020-07-17
UY38851A (es) 2021-02-26
CA3148978A1 (en) 2021-02-25
ECSP22021881A (es) 2022-04-29
EP4019047A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
CO2019014484A2 (es) Nuevos derivados de azaquinolina
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CO2017008765A2 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih
BR112020020708A8 (pt) Derivados da ureia cíclica fundidã como antagonista crhr2
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
CO2022001829A2 (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
CL2018002368A1 (es) Formulaciones de oritavancina
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
BR112017015474A2 (pt) inibidores de bace1
BR112022010204A2 (pt) Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo
ECSP21027009A (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento